SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced several senior management promotions and team expansion.
“Twist is growing at a significant rate, meeting and exceeding important milestones and building value. This can only be achieved with strong leadership and a dedicated workforce. The executive team promotions and additions announced today reflect the dedication of each person to Twist and their role in supporting our stakeholders,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
Executive Team Promotions and Additions
Siyuan Chen has been promoted to Chief Technology Officer in recognition for his leadership of the chemistry and biochemistry R&D efforts and interdisciplinary projects, as well as his strategic vision and implementation of both the SynBio and NGS product lines and conceptualizing Twist’s synthetic RNA controls for SARS-CoV-2. In this extension of his previous role, he will outline Twist’s technological vision and effectively implement technology strategies that bring competitive advantages to Twist from a product and market opportunity perspective.
Aaron Sato has been promoted to Chief Scientific Officer (CSO) of Twist Bioscience. In his new company-wide science leadership role, he will drive the creation of new custom protein and cell-based products stemming from Twist’s DNA synthesis platform, including high throughput IgG. In addition, he will continue in his operational role as CSO of Twist Biopharma, where he manages teams to discover and develop novel first-in-class antibody therapeutics for Twist and our partners.
Paula Green has been promoted to Senior Vice President, Human Resources (HR) to recognize her advancement of the HR function at Twist. In this role, she has developed strategy, implemented new programs to attract and retain employees worldwide, enhanced the employee healthcare benefits scheme, facilitated communication across internal teams, propagated and maintained Twist’s differentiated culture during a time of high growth, initiated a diversity and inclusion program, in addition to many other accomplishments over her tenure at Twist.
Angela Bitting has joined the company as Senior Vice President of Corporate Affairs. This follows working for Twist for six years as a consultant leading external communications. In addition to these responsibilities, in her new role, she will lead investor relations and internal communications. Prior to Twist, she led her own strategic communications consultancy for almost 20 years, working with a broad range of executives in the healthcare field across therapeutic, diagnostic, and device companies.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein may be deemed to be forward-looking statements, including, but not limited to: Twist’s growth rate, achievement of important milestones and value creation. These statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk that the facility does not become operational on the expected time frame or at all due to construction or other delays, as well as the risks and uncertainties set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 27, 2020 and subsequent filings with the SEC. risks and uncertainties set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 27, 2020 and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Twist Bioscience’s results of operations, which would, in turn, have a significant and adverse impact on Twist Bioscience’s stock price. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.